{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-033861","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2026-05-12T11:05:23+00:00","discovered_at":"2026-05-12T11:10:00.362945+00:00","generated_at":"2026-05-12T11:13:26.176983+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"C4 Therapeutics Q1 2026 net loss $25.1M; cash $268.3M; new Roche DAC collaboration","bullets":["Revenue $6.2M (down from $7.2M YoY); net loss $25.1M ($0.20 EPS) vs $26.3M ($0.37 EPS).","Cash $268.3M at March 31, 2026; runway to end of 2028.","Decision to not advance CFT8919 (EGFR L858R degrader) outside Greater China.","New collaboration with Roche for degrader-antibody conjugates; $20M upfront payment received.","Cemsidomide Phase 2 MOMENTUM trial enrollment on track; Phase 1b with elranatamab first patient dosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-033861","json":"https://secwatch.observer/filing/0001628280-26-033861.json","markdown":"https://secwatch.observer/filing/0001628280-26-033861.md","text":"https://secwatch.observer/filing/0001628280-26-033861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026033861/0001628280-26-033861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026033861/cccc-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:13:26.176983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dad074d512537f7ca361fa57a6ebebc99cccba48","claim":"C4 Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $6.2 million, net income $25.1 million.","evidence_excerpt":"Global Healthcare Conference taking place in Miami, FL from June 8 - 10, 2026. FIRST QUARTER 2026 FINANCIAL RESULTS Revenue: Total revenue for the first quarter of 2026 was $6.2 million, compared to $7.2 million for the first quarter of 2025. The decrease in revenue resulted from the conclusion of the research collaboration with Merck and the prioritization of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026033861/0001628280-26-033861-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$6.2 million"},{"label":"Net income","value":"$25.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}